Solventum Corporation

SOLV Healthcare Medical Instruments & Supplies

Solventum Corporation’s revenue for fiscal 2025 (year ended December 2025) was $8.3 billion, up 0.86% from fiscal 2024. In the quarter to June 2026, revenue grew 2.22%, EPS grew 1.92%, free cash flow grew 144.1% and total debt fell 32.4%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for three consecutive years; insiders bought in the last twelve months.

85.81 2.05 −2.33%
Market cap
$15.0B
P/E
10.4×
Fwd P/E
39.0×
Dividend yield
—
F-score
5/9
Altman Z
2.22
Beneish M
−2.07
Dividend safety
n/a

Solventum Corporation (SOLV) Return on assets

Alert me on Return on assets

Solventum Corporation's return on assets over the twelve months to 30 June 2026 was 9.78%, down 1.0 percentage points from fiscal 2025 (10.8%). That is above the Medical Instruments & Supplies industry median of 0.00% and above the Healthcare sector median of −30.9%.

Return on assets, annual

Embed this chart

Annual newest first

Period Return on assets Change (points)
FY2025 10.8% 7.45
FY2024 3.37% (15.94)
FY2023 19.3% 19.31
FY2022 0.00% —

Return on assets against peers

Company Return on assets
WST West Pharmaceutical Services, Inc. compare 14.1%
SOLV Solventum Corporation 9.78%
ATR AptarGroup, Inc. compare 7.25%
ALGN Align Technology, Inc. compare 6.55%
COO The Cooper Companies, Inc. compare 4.55%
ALC Alcon compare 2.06%
RGEN Repligen Corporation compare 1.42%
AVTR Avantor, Inc. compare −4.74%
BAX Baxter International Inc. compare −5.21%
Medical Instruments & Supplies industry median 0.00%
Healthcare sector median −30.9%
Market median 0.00%

What Return on assets is

ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.

Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)

The full definition of Return on assets →

More on SOLV